

3.0 Gy 10 Day Schedule and Duration of Therapy
Options:
Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su
WBRT
A: ABT-888
1 2 3 4 5 Rest 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10 11 12 13
WBRT
B: ABT-888
1 2 3 4 Rest 5 6 7 8 9 Rest 10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
WBRT
C: ABT-888
1 2 3 Rest 4 5 6 7 8 Rest 9 10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
WBRT
D: ABT-888
1 2 Rest 3 4 5 6 7 Rest 8 9 10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
WBRT
E: ABT-888
1 Rest 2 3 4 5 6 Rest 7 8 9 10
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
2.5 Gy 15 Day Schedule and Duration of Therapy
Options:
Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su Mo Tu We Th Fr Sa Su
WBRT
A: ABT-888
1 2 3 4 5 Rest 6 7 8 9 10 Rest 11 12 13 14 15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
WBRT
B: ABT-888
1 2 3 4 Rest 5 6 7 8 9 Rest 10 11 12 13 14 Rest 15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
WBRT
C: ABT-888
1 2 3 Rest 4 5 6 7 8 Rest 9 10 11 12 13 Rest 14 15
1 2 3 4 5 6 7 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22
WBRT
D: ABT-888
1 2 Rest 3 4 5 6 7 Rest 8 9 10 11 12 Rest 13 14 15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
WBRT
E: ABT-888
1 Rest 2 3 4 5 6 Rest 7 8 9 10 11 Rest 12 13 14 15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

FIG. 1

Preliminary Mean ± SD Pharmacokinetic Parameters of Veliparib Following WBRT in Patients with Brain Metastases

Parameter	Veliparib Dose (mg BID)											
	10		20		30		50		80		100	150
Day 1												
N	6		6		6		9		6		8	6
C_{max} (μg/mL)	0.07 ± 0.02		0.11 ± 0.04		0.22 ± 0.08		0.32 ± 0.09		0.46 ± 0.17		0.89 ± 0.45	1.39 ± 0.68
T_{max} (h)	1.1 ± 0.7		2.0 ± 2.0		2.0 ± 2.0		1.9 ± 0.3		1.5 ± 0.5		1.9 ± 1.7	1.5 ± 1.7
AUC_{0-6} (μg•h/mL)	0.21 ± 0.04		0.44 ± 0.22		0.79 ± 0.33[c]		1.27 ± 0.39		1.77 ± 0.48		3.13 ± 1.26	4.74 ± 2.15[d]
Day 6 (Fasting)												
N	6		5		5		9		4		9	7
C_{max} (μg/mL)	0.05 ± 0.01		0.13 ± 0.02		0.28 ± 0.11		0.45 ± 0.16		0.53 ± 0.14		1.07 ± 0.42	1.66 ± 0.89
T_{max} (h)	1.8 ± 0.4		1.4 ± 0.6		0.9 ± 0.7		1.2 ± 0.6		0.8 ± 0.3		1.1 ± 0.5	1.2 ± 0.6
AUC_{0-6} (μg•h/mL)	0.25 ± 0.04[b]		0.53 ± 0.06		1.20 ± 0.24[c]		1.80 ± 0.62		2.08 ± 0.76		4.25 ± 1.63	7.78 ± 5.07[e]
AUC_{0-12} (μg•h/mL)[a]	0.39 ± 0.06[b]		0.82 ± 0.10		1.93 ± 0.77[c]		2.70 ± 0.91		3.10 ± 1.34		6.16 ± 2.27	12.4 ± 8.62[e]
Day 15 (Non-Fasting)												
N	6		4		4		9		4		7	6
C_{max} (μg/mL)	0.07 ± 0.02		0.11 ± 0.03		0.25 ± 0.08		0.44 ± 0.13		0.47 ± 0.08		0.91 ± 0.27	1.50 ± 0.84
T_{max} (h)	2.3 ± 1.9		2.0 ± 0.0		1.8 ± 0.5		1.9 ± 1.7		2.0 ± 0.0		2.6 ± 1.5	2.7 ± 1.6
AUC_{0-6} (μg•h/mL)	0.27 ± 0.65		0.50 ± 0.11		1.16 ± 0.52		1.90 ± 0.72[d]		1.92 ± 0.52		3.79 ± 1.14	6.86 ± 4.16
AUC_{0-12} (μg•h/mL)[a]	0.43 ± 0.06		0.82 ± 0.14		2.01 ± 1.10		3.05 ± 1.22[d]		3.15 ± 1.24		6.11 ± 1.84	11.6 ± 7.24

FIG. 2





Preliminary Veliparib Mean Plasma Concentration–Time Profiles Following Oral Administration of Veliparib
Days 1
Days 6
Days 15
10 MG (N=6)
20 MG (N=6)
30 MG (N=6)
50 MG (N=9)
80 MG (N=6)
100 MG (N=8)
150 MG (N=10)
Mean (SD) Veliparib Plasma Concentration (µg/mL)
3.0
2.5
2.0
1.5
1.0
0.5
0.0
0 1 2 3 4 5 6 24
0 1 2 3 4 5 6
Time (h)

FIG.3




*10 Patients Did Not Have Post Baseline Tumor Measurement, Where Available, Best Tumor Response is Presented Below:
i. 3 Patients (224[CR], 258[SD], 258[SD]) Did Not Have Measurable Disease at Baseline
ii. 3 Patients (235[SD], 207[PR], 215[SD]) Did Not Have Post Baseline Tumor Measurement
iii. 3 Patients (247, 211, 262) Did Not Have Post Baseline Tumor Evaluation
iiii. 1 Patients (270) Is Still Ongoing: Post Baseline Tumor Evaluation Has Not Been Performed

FIG. 4



* 5 Patients Did Not Have Post Baseline Tumor Measurement, Where Available, Best Tumor Response is Presented Below:
i. 2 Patients (208[SD] And 241) Did Not Have Measurable Disease at Baseline
ii. 1 Patients (221) Did Not Have Post Baseline Tumor Measurement
iii. 2 Patients (237 And 265) Did Not Have Post Baseline Tumor Evaluation

FIG. 5



12 Patients Did Not Have Post Baseline Tumor Measurement, Their Best Tumor Response is in the Parentheses if Data Available:
i. 4 Patients (220(SD), 205(SD), 201(SD), 255(PR)) Did Not Have Measurable Disease at Baseline.
ii. 1 Patients (260) Did Not Have Post Baseline Tumor Measurement Entered in eCRFs.
iii. 5 Patients (250, 236, 266, 228, 210) Did Not Have Post Baseline Tumor Evaluation.
iiii. 2 Patients (267, 269) Are Still Ongoing: Post Baseline Tumor Evaluation Has Not Been Performed.

FIG.6



Overall Survival for Patients with NSCLC
+ Censored
Subjects (N=23)
Event (%) 13(56.5%)
Median Months (95% CI) 6.6(3.3, 13.0)
6-Month OS Rate (95% CI): 54.5%(30.4%, 73.4%)
12-Month OS Rate (95% CI): 34.6%(13.8%, 56.7%)
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Months
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
At Risk 23 20 16 15 13 10 9 8 7 7 6 5 5 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 *

FIG. 7



Overall Survival of Responders vs Non-Responders (Patients with NSCLC)
Non-Responder (N=12)
Responder (N=7)
Event (%) 8(66.7%) 4(57.1%)
Median Months (95% CI) 3.3(0.9, -) 11.7(6.6, 13.0)
Responder vs. Non-Responder
Log-Rank P=0.105
Hazard Ratio (95% C.I.) 0.359(0.100, 1.287)
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
+ Censored
Non-Responder
Responder
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Months
At Risk
Non-Responder 12 10 7 6 4 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0
Responder 7 7 6 6 6 6 6 5 5 5 4 3 3 0

FIG.8



Overall Survival for Patients with Breast Cancer
+ Censored
Subjects (N=21)
Event (%) 13(61.9%)
Median Months (95% CI) 8.3(2.8, 16.9)
6-Month OS Rate (95% CI): 69.2%(43.7%, 84.9%)
12-Month OS Rate (95% CI): 47.3%(24.1%, 67.4%)
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Months
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
At Risk 21 21 17 14 14 13 13 12 10 8 8 8 8 6 3 2 2 2 1 0

FIG.9



Overall Survival of Responders vs Non-Responders (Patients with Breast Cancer)
Survival Probability
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
+ Censored
Non-Responder
Responder
Non-Responder (N=9)
Responder (N=9)
Event (%) 6(66.7%) 6(66.7%)
Median Months (95% CI) 6.2(1.0, -) 12.5(2.8, 16.9)
Responder vs. Non-Responder
Log-Rank P=0.560
Hazard Ratio (95% C.I.) 0.710(0.223, 2.259)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Months
At Risk
Non-Responder 9 9 7 5 5 4 4 3 3 3 3 3 3 2 1 1 1 0
Responder 9 9 9 8 8 8 8 6 4 4 4 4 2 1 1 1 0

FIG. 10



Observed vs. Expected Survival -- NSCLC
Predicted
Observed
Predicted (N=32)
Observed (N=32)
Events 32(100.0%) 20(62.5%)
Median Days (95% CI) 109(97, 119) 304(111, 410)
Log-Rank P-Value P=<0.001***
Observed Overall Survival
Predicted Overall Survival (Case Controlled)
+ : Censored Observation
Probability of Survival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600 630 660 690 720 750 780 810 840 870 900
Survival Days
Pts at Risk
Predicted 32 32 32 29 10 4
Observed 32 30 30 25 21 20 17 15 12 12 10 7 7 7 6 3 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

FIG. 11



Observed vs. Expected Survival -- Breast Cancer
Predicted
Observed
Predicted (N=25)
Observed (N=25)
Events 25(100.0%) 18(72.0%)
Median Days (95% CI) 172(161, 183) 233(86, 455)
Log-Rank P-Value P=0.005**
Probability of Survival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
| : Censored Observation
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600 630 660 690 720 750 780 810 840 870 900
Survival Days
Pts at Risk
Predicted 25 25 25 24 23 19 11 4 3 1
Observed 25 25 21 16 16 14 14 13 11 9 8 8 8 6 5 4 3 3 2 2 1 1 1 1 1 1 1 1

FIG. 12